Rosiglitazone Doubles Risk of Heart Failure

Medical News: ADA: Rosiglitazone Increases Risk of Heart Failure, but Not Mortality – in Meeting Coverage, ADA from MedPage Today

Take Home Lesson:

Consider simply adding the usual recommended debits for CHF to the DM rate.

After all, the HF risk is doubled but not the mortality.  And critics of this study question its statistical validity.

Leave a comment